BELBUCA

Peak

buprenorphine hydrochloride

Teva

NDABUCCALFILM

Approved

Oct 2015

Lifecycle

Peak

Competitive Pressure

0/100

Data completeness

6/8 — Strong

BELBUCA (buprenorphine hydrochloride) by Teva is mu-opioid receptor and an antagonist at the kappa-opioid receptor. Approved for opioid use disorder. First approved in 2015.

Drug data last refreshed 19h ago · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

BELBUCA is a buccal film formulation of buprenorphine hydrochloride approved in October 2015 for the management of severe, persistent pain in patients requiring opioid therapy. It functions as a mu-opioid receptor agonist and kappa-opioid receptor antagonist, providing analgesic effects through a unique buccal delivery mechanism. The product represents an alternative to immediate-release opioids and other sustained-release formulations in the chronic pain management market.

$0.1BPart D

6.6 years to LOE

Mechanism of Action

mu-opioid receptor and an antagonist at the kappa-opioid receptor.

Indications (1)

Opioid Use Disorder(3)

Why This Matters for Your Career

Worked on BELBUCA at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Career Relevance

BELBUCA supports roles including brand managers focused on chronic pain markets, medical science liaisons (MSLs) engaging pain specialists and primary care, and field sales teams. Key competencies include opioid prescribing regulations, chronic pain management protocols, patient access navigation, and payer management in the Part D space. Currently zero open positions are linked to this product in available data, suggesting stable commercial operations without active expansion recruitment.